Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOA | P21397 | 1/20 | 0.33 |
| ▸ | MAOB | P27338 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.32 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.32 |
| ▸ | DYRK1B | Q9Y463 | 1/20 | 0.32 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.31 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.31 |
| ▸ | LMNA | P02545 | 1/20 | 0.31 |
| ▸ | GRM5 | P41594 | 2/20 | 0.30 |
| ▸ | GAA | P10253 | 2/20 | 0.30 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.30 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19153122 | 0.75 | MAOA (0.41) | MAOAMAOBDYRK1ADYRK1BTAAR1 | |
| SCHEMBL8288513 | 0.72 | MAOA (0.35) | MAOAMAOBDYRK1ADYRK1BLMNA | |
| SCHEMBL23566352 | 0.72 | NOS3 (0.41) | MAOAMAOBDYRK1ADYRK1B | |
| SCHEMBL18238925 | 0.72 | MAOA (0.36) | MAOAMAOBDYRK1ADYRK1B | |
| SCHEMBL23566351 | 0.67 | HSP90AA1 (0.35) | MAOAMAOBDYRK1ADYRK1BGAA | |
| SCHEMBL4467990 | 0.65 | MAOB (0.38) | MAOAMAOBMAPTKDM4E | |
| SCHEMBL13021607 | 0.63 | MAOA (0.49) | MAOAMAOBMAPTDYRK1ADYRK1B | |
| SCHEMBL9145281 | 0.62 | PTK2 (0.37) | MAPTDYRK1ADYRK1BKDM4ELMNA | |
| SCHEMBL8799078 | 0.61 | DRD1 (0.32) | — | |
| SCHEMBL4808073 | 0.61 | DYRK1A (0.39) | MAOAMAOBDYRK1ADYRK1BGAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7601736-B2 | Such as 3,4-dihydro-pyrano[3,4-c]pyridine-1-on; cytokine suppressive antiinflammatory drugs; analgesics | SK CHEMICALS CO., LTD. (KR) | 2009-10-13 | — | — | US | disclosed |
| US-20070254909-A1 | Novel Pyridine Derivatives, a Process for Their Preparation and a Pharmaceutical Composition Containing the Same | SK CHEMICALS CO., LTD. (KR) | 2007-11-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070254909-A1 | Novel Pyridine Derivatives, a Process for Their Preparation and a Pharmaceutical Composition Containing the Same | IL5, IL1B, P2RY4 | MAOA 662/4885MAOB 760/4885MAPT 1573/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.